Testing a new study drug for progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new study drug added to your current MS treatment (ocrelizumab) for people with progressive MS. It aims to see if the combination works better than ocrelizumab alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with progressive multiple sclerosis (MS).
- Your disability level is between 3.0 and 6.0 on the Expanded Disability Status Scale (EDSS).
- You have not had an MS relapse in the last 6 months.
- You are able to complete an MRI scan.
- You have not received intravenous immunoglobulin (IVIg) or plasma exchange in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
This study tests an experimental drug given as an injection under the skin for people with relapsing multiple sclerosis (MS). The goal is to see if it can reduce relapses and slow down the disease.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.